Nektar Therapeutics (NASDAQ: NKTR) Investor Securities Class Action Lawsuit 10/30/2018

If you purchased a significant amount of shares of Nektar Therapeutics (NASDAQ: NKTR) between November 11, 2017, and October 2, 2018, and / or if you purchased any NASDAQ: NKTR shares prior to November 2017and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: December 31, 2018. NASDAQ: NKTR investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Nektar Therapeutics
Case Name: 
Nektar Therapeutics Shareholder Class Action Lawsuit 10/30/2018
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: NKTR
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
10/31/2018
Class Period End: 
11/11/2017
Class Period Begin: 
10/02/2018
Court of Filing: 
U.S. District Court for the Northern District of California
Deadline To File for Lead: 
12/31/2018
Summary: 

An investor in shares of Nektar Therapeutics (NASDAQ: NKTR) filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by Nektar Therapeutics in connection with certain allegedly false and misleading statements made between November 11, 2017, and October 2, 2018.

San Francisco, CA based Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. NKTR-214, is the Company’s lead immune-oncology (“I-O”) candidate, is a biologic with biased signaling through one of the IL-2 receptor subunits (CD 122) that can stimulate proliferation and growth of tumor-killing immune cells in the tumor microenvironment and increase expression of PD-1 on these immune cells.

On October 1, 2018, Plainview LLC published a report raising questions about Nektar Therapeutics’ claims concerning its clinical stage drug, NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer, and its ability to effectively treat cancer.

Shares of Nektar Therapeutics (NASDAQ: NKTR) declined to as low as $51.74 per share on October 4, 2018.

According to the complaint the plaintiff alleges on behalf of purchasers of Nektar Therapeutics (NASDAQ: NKTR) common shares between November 11, 2017, and October 2, 2018, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between November 11, 2017, and October 2, 2018, the Defendants made false and/or misleading statements and/or failed to disclose that prior studies which attempted to pegylate IL-2 failed, that NKTR-214’s extended half-life was unlikely to result in efficacy and created additional high-dosing safety concerns, that NKTR-214 was less effective than IL-2 alone, that the combination of NKTR-214 with nivolumab has not yet demonstrated significant positive results, and that as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.